A Phase 1, Open Label, Randomized, Multiple Ascending Dose (MAD) Study Evaluating the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
Latest Information Update: 03 Jun 2025
At a glance
- Drugs Fulvestrant (Primary) ; Fulvestrant (Primary) ; KSHN 001034 (Primary) ; KSHN 001034 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Kashiv BioSciences
Most Recent Events
- 03 Jun 2025 New trial record